文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

双重免疫检查点阻断的实施提高了头颈癌诱导化疗的反应率。

Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer.

作者信息

Semrau Sabine, Gostian Antoniu-Oreste, Traxdorf Maximilian, Eckstein Markus, Rutzner Sandra, von der Grün Jens, Illmer Thomas, Hautmann Matthias, Klautke Gunther, Laban Simon, Brunner Thomas, Tamaskovics Bálint, Frey Benjamin, Zhou Jian-Guo, Geppert Carol-Immanuel, Hartmann Arndt, Balermpas Panagiotis, Budach Wilfried, Gaipl Udo, Iro Heinrich, Fietkau Rainer, Hecht Markus

机构信息

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

Department of Otorhinolaryngology-Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Bayern, Germany.

出版信息

Cancers (Basel). 2021 Apr 19;13(8):1959. doi: 10.3390/cancers13081959.

DOI:10.3390/cancers13081959
PMID:33921668
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8073509/
Abstract

To determine whether a single dose of double immune checkpoint blockade (induction chemoimmunotherapy (ICIT)) adds benefit to induction single-cycle platinum doublet (induction chemotherapy (IC)) in locally advanced head and neck squamous cell carcinoma (HNSCC), patients treated with cisplatin 30 mg/m d1-3 and docetaxel 75 mg/m d1 combined with durvalumab 1500 mg fixed dose d5 and tremelimumab 75 mg fixed dose d5 (ICIT) within the CheckRad-CD8 trial were compared with a retrospective cohort receiving the same chemotherapy (IC) without immunotherapy. The endpoint of this analysis was the complete response rate (CR). A total of 53 patients were treated with ICIT and 104 patients with IC only. CR rates were 60.3% for ICIT and 40.3% for IC ( = 0.018). In the total population ( = 157), the most important predictor to achieve a CR was treatment type (OR: 2.21 for ICIT vs. IC; = 0.038, multivariate analysis). The most diverse effects in CR rates between ICIT and IC were observed in younger (age ≤ 60) patients with HPV-positive OPSCCs (82% vs. 33%, = 0.176), while there was no difference in older patients without HPV-positive OPSCCs (53% vs. 48%). The analysis provides initial evidence that ICIT could result in higher CR rates than IC. Young patients with HPV-positive OPSCCs may have the greatest benefit from additional immune checkpoint inhibitors.

摘要

为了确定单剂量双重免疫检查点阻断（诱导化疗免疫疗法（ICIT））是否能为局部晚期头颈部鳞状细胞癌（HNSCC）的诱导单周期铂类双联化疗（诱导化疗（IC））带来更多益处，在CheckRad-CD8试验中，将接受顺铂30mg/m² d1-3和多西他赛75mg/m² d1联合度伐利尤单抗1500mg固定剂量d5以及曲美木单抗75mg固定剂量d5（ICIT）治疗的患者与接受相同化疗（IC）但未进行免疫治疗的回顾性队列进行了比较。该分析的终点是完全缓解率（CR）。共有53例患者接受了ICIT治疗，104例患者仅接受了IC治疗。ICIT组的CR率为60.3%，IC组为40.3%（P = 0.018）。在总人群（n = 157）中，实现CR的最重要预测因素是治疗类型（ICIT与IC相比的OR：2.21；P = 0.038，多变量分析）。在年轻（年龄≤60岁）的HPV阳性口咽鳞状细胞癌（OPSCC）患者中，观察到ICIT和IC之间CR率的差异最大（82%对33%，P = 0.176），而在无HPV阳性OPSCC的老年患者中没有差异（53%对48%）。该分析提供了初步证据，表明ICIT可能比IC导致更高的CR率。年轻的HPV阳性OPSCC患者可能从额外的免疫检查点抑制剂中获益最大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc79/8073509/85a324a4ec67/cancers-13-01959-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc79/8073509/85a324a4ec67/cancers-13-01959-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc79/8073509/85a324a4ec67/cancers-13-01959-g001.jpg

相似文献

[1]
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer.

Cancers (Basel). 2021-4-19

[2]
Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer.

Cancers (Basel). 2022-9-30

[3]
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.

J Immunother Cancer. 2020-10

[4]
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial.

Neoplasia. 2024-3

[5]
A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).

Oral Oncol. 2017-6-16

[6]
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.

Oral Oncol. 2006-8

[7]
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.

Korean J Intern Med. 2016-5

[8]
Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.

Oral Oncol. 2016-3

[9]
[Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].

Zhonghua Zhong Liu Za Zhi. 2015-9

[10]
Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.

Eur Arch Otorhinolaryngol. 2019-10-3

引用本文的文献

[1]
Identification and validation of a KRAS-macrophage-associated gene signature as prognostic biomarkers and potential therapeutic targets in melanoma.

Front Immunol. 2025-6-18

[2]
Non-surgical organ preservation and new technologies in laryngeal radiation.

Front Oncol. 2025-3-17

[3]
Future investigative directions for novel therapeutic targets in head and neck cancer.

Expert Rev Anticancer Ther. 2024-11

[4]
Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review).

Oncol Lett. 2023-7-17

[5]
Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report.

Medicine (Baltimore). 2023-8-4

[6]
Radiotherapy-Dose Escalated for Large Volume Primary Tumors-And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck-A Randomized Phase II Trial.

Cancers (Basel). 2023-4-28

[7]
CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus-Driven Oropharyngeal Cancer.

Cancer Immunol Res. 2023-3-1

[8]
Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer.

Oncol Lett. 2022-12-7

[9]
Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo.

Int J Mol Sci. 2022-2-25

[10]
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.

J Immunother Cancer. 2022-1

本文引用的文献

[1]
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.

J Immunother Cancer. 2020-10

[2]
The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites.

Curr Oncol Rep. 2020-6-29

[3]
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

Ann Oncol. 2020-7

[4]
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.

Clin Cancer Res. 2020-7-1

[5]
Influence of radiation dose to pharyngeal constrictor muscles on late dysphagia and quality of life in patients with locally advanced oropharyngeal carcinoma.

Strahlenther Onkol. 2020-1-31

[6]
Analysis of the immune status from peripheral whole blood with a single-tube multicolor flow cytometry assay.

Methods Enzymol. 2020

[7]
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Lancet. 2019-11-1

[8]
Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.

Eur Arch Otorhinolaryngol. 2019-10-3

[9]
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.

J Exp Clin Cancer Res. 2019-6-13

[10]
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Eur J Cancer. 2018-12-18

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索